Overview

Clinical Study of IBI362 in Healthy Chinese Male Subjects

Status:
Completed
Trial end date:
2021-06-17
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.